versus MET, PIO, and SITA monotherapyin patients with type 2 diabetes who weresuboptimally treated with diet and exer-cise but naive to antihyperglycemicdrugs. cccccccccccccccccccccccccccccccccccccccccccccccc  From the1Department of Diabetes and Endocrinology, Royal Surrey County Hospital, University of Surrey, Guildford, U.K.; the2International Diabetes Center, Park Nicollet Clinic, Minneapolis, Minnesota; the 3Center for Clinical Studies, Technical University Dresden, Dresden, Germany; the4Diabetes Care and Research Center, Patna, India; the5Department of Endocrinology, University Hospital, Monterrey, Mexico; and6Eli Lilly and Company, Indianapolis, Indiana. Corresponding author: Marilyn K. Boardman, mkboardman@lilly.com. Received 13 June 2011 and accepted 9 November 2011.DOI: 10.2337/dc11-1107. Clinical trial reg. no. NCT00676338, clinicaltrials.gov.This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1107/-/D 1.